These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33288854)

  • 1. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression.
    Di Domenico A; Pipinikas CP; Maire RS; Bräutigam K; Simillion C; Dettmer MS; Vassella E; Thirlwell C; Perren A; Marinoni I
    Commun Biol; 2020 Dec; 3(1):740. PubMed ID: 33288854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
    Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
    Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
    Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
    J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
    Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
    Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
    Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
    Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.
    Simon T; Riemer P; Jarosch A; Detjen K; Di Domenico A; Bormann F; Menne A; Khouja S; Monjé N; Childs LH; Lenze D; Leser U; Rossner F; Morkel M; Blüthgen N; Pavel M; Horst D; Capper D; Marinoni I; Perren A; Mamlouk S; Sers C
    Genome Med; 2022 Mar; 14(1):24. PubMed ID: 35227293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.
    Kajtazi Y; Kaemmerer D; Sänger J; Schulz S; Lupp A
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2481-2493. PubMed ID: 31451931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.
    Hong X; Qiao S; Li F; Wang W; Jiang R; Wu H; Chen H; Liu L; Peng J; Wang J; Jia C; Liang X; Dai H; Jiang J; Zhang T; Liao Q; Dai M; Cong L; Han X; Guo D; Liang Z; Li D; Zheng Z; Ye C; Li S; Zhao Y; Wu K; Wu W
    Gut; 2020 May; 69(5):877-887. PubMed ID: 31462556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
    Marini F; Giusti F; Brandi ML
    Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT).
    Neyaz A; Crotty R; Rickelt S; Pankaj A; Stojanova M; Michelakos TP; Sekigami Y; Kontos F; Parrack PH; Patil DT; Heaphy CM; Ferrone CR; Deshpande V
    Histopathology; 2023 Oct; 83(4):546-558. PubMed ID: 37455385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
    Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
    Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data.
    Kit OI; Trifanov VS; Petrusenko NA; Gvaldin DY; Kutilin DS; Timoshkina NN
    Mol Biol Rep; 2020 Jun; 47(6):4233-4243. PubMed ID: 32451928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dictating genomic destiny: Epigenetic regulation of pancreatic neuroendocrine tumours.
    Gundara JS; Jamal K; Kurzawinski T
    Mol Cell Endocrinol; 2018 Jul; 469():85-91. PubMed ID: 28385665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypo-methylation mediates chromosomal instability in pancreatic NET.
    Marinoni I; Wiederkeher A; Wiedmer T; Pantasis S; Di Domenico A; Frank R; Vassella E; Schmitt A; Perren A
    Endocr Relat Cancer; 2017 Mar; 24(3):137-146. PubMed ID: 28115389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.
    Takano Y; Kasai K; Takagishi Y; Kikumori T; Imai T; Murata Y; Hayashi Y
    PLoS One; 2015; 10(7):e0133812. PubMed ID: 26192435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization.
    Capodanno Y; Chen Y; Schrader J; Tomosugi M; Sumi S; Yokoyama A; Hiraoka N; Ohki R
    Neoplasia; 2021 Sep; 23(9):979-992. PubMed ID: 34352404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy.
    Estrella JS; Ma LT; Milton DR; Yao JC; Wang H; Rashid A; Broaddus RR
    Pancreas; 2014 Oct; 43(7):996-1002. PubMed ID: 25058880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
    Ohki R; Saito K; Chen Y; Kawase T; Hiraoka N; Saigawa R; Minegishi M; Aita Y; Yanai G; Shimizu H; Yachida S; Sakata N; Doi R; Kosuge T; Shimada K; Tycko B; Tsukada T; Kanai Y; Sumi S; Namiki H; Taya Y; Shibata T; Nakagama H
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2404-13. PubMed ID: 24912192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.
    Chan CS; Laddha SV; Lewis PW; Koletsky MS; Robzyk K; Da Silva E; Torres PJ; Untch BR; Li J; Bose P; Chan TA; Klimstra DS; Allis CD; Tang LH
    Nat Commun; 2018 Oct; 9(1):4158. PubMed ID: 30315258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.